Author

Lucia De Franceschi

Associated professor of Internal medicine - Cited by 21,028 - Internal Medicine - Non-oncological hematology - red cell disorders and erythropoiesis

Biography

Dr Lucia De Franceschi is working as an Associate Professor in Internal Medicine at the University of Verona, Itlay. Through highly productive collaborations and keywork in her laboratory, her research has resulted in a number of breakthrough technologies and discoveries.  
Title
Cited by
Year
Recommendations for diagnosis and treatment of methemoglobinemia
A Iolascon, P Bianchi, I Andolfo, R Russo, W Barcellini, E Fermo, G Toldi, ...American journal of hematology 96 (12), 1666-1678, 2021202
40
2021
The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a β-thalassemia mouse model
A Matte, E Federti, C Kung, PA Kosinski, R Narayanaswamy, R Russo, ...The Journal of clinical investigation 131 (10), 2021202
27
2021
Therapeutic targeting of Lyn kinase to treat chorea-acanthocytosis
K Peikert, E Federti, A Matte, G Constantin, EC Pietronigro, PF Fabene, ...Acta Neuropathologica Communications 9 (1), 1-, 2021202
15
2021
Pharmacological Induction of Fetal Hemoglobin in β-Thalassemia and Sickle Cell Disease: An Updated Perspective
R Bou-Fakhredin, L De Franceschi, I Motta, MD Cappellini, AT TaherPharmaceuticals 15 (6), 753, 2022202
8
2022
Premature aging of the immune system affects the response to SARS-CoV-2 mRNA vaccine in β-thalassemia: role of an additional dose
R Carsetti, C Agrati, VM Pinto, B Gianesin, R Gamberini, M Fortini, ...Blood, The Journal of the American Society of Hematology 140 (15), 135-138, 2022202
7
2022
Italian patients with hemoglobinopathies exhibit a 5‐fold increase in age‐standardized lethality due to SARS‐CoV‐2 infection
F Longo, B Gianesin, V Voi, I Motta, VM Pinto, A Piolatto, A Spasiano, ...American Journal of Hematology 9 (2), E5-E8, 2022202
7
2022
Targeting Lyn kinase in chorea-acanthocytosis: a translational treatment approach in a rare disease
K Peikert, H Glaß, E Federti, A Matte, L Pelzl, K Akgün, T Ziemssen, ...Journal of Personalized Medicine 11 (5), 392, 2021202
7
2021
Novel inhibitors of human glucose-6-phosphate dehydrogenase (HsG6PD) affect the activity and stability of the protein
Novel inhibitors of human glucose--phosphate dehydrogenase (HsGPD) affect the activity and stability of the proteinEJ Ramírez-Nava, B Hernández-Ochoa, G Navarrete-Vázquez, ...Biochimica et Biophysica Acta (BBA)-General Subjects 185 (3), 129828, 2021202
6
2021
Evidence of protective effects of recombinant ADAMTS13 in a humanized model of sickle cell disease
P Rossato, E Federti, H Glantschnig, F Canneva, M Schuster, S Coulibaly, ...Haematologica 107 (11), 250, 2022202
6
2022
Evidence of noninferiority of mitapivat versus splenectomy in murine hereditary spherocytosis
A Matte, E Federti, PA KosinskiEHA. Wein: Hemasphere 6, 174-17, 2022202
5
2022
Adaptative Up-regulation of PRX2 and PRX5 expression characterizes brain from a mouse model of chorea-acanthocytosis
Adaptative Up-regulation of PRX2 and PRX expression characterizes brain from a mouse model of chorea-acanthocytosisE Federti, A Matte, V Riccardi, K Peikert, SL Alper, A Danek, RH Walker, ...Antioxidants 11 (1), 76, 2021202
5
2021
The EHA research roadmap: anemias
A Iolascon, S Rivella, NP Anagnou, C Camaschella, D Swinkels, ...Hemasphere 5 (7), 2021202
4
2021
Selecting β-thalassemia patients for gene therapy: a decision-making algorithm
D Baronciani, M Casale, L De Franceschi, G Graziadei, F Longo, R Origa, ...HemaSphere 5 (5), 2021202
4
2021
Tyrosine phosphorylation modulates peroxiredoxin-2 activity in normal and diseased red cells
A Mattè, E Federti, E Tibaldi, ML Di Paolo, G Bisello, M Bertoldi, ...Antioxidants 10 (2), 206, 2021202
4
2021
Morbidity and mortality of sickle cell disease patients is unaffected by splenectomy: evidence from three decades of follow-up in a high-income setting
VM Pinto, B Gianesin, FB Piel, F Longo, P Rigano, A Quota, V Spadola, ...Haematologica 108 (), 1158, 2023202
4
2023
Dietary ω-3 fatty acid supplementation improves murine sickle cell bone disease and reprograms adipogenesis
Dietary ω- fatty acid supplementation improves murine sickle cell bone disease and reprograms adipogenesisMT Valenti, A Mattè, E Federti, M Puder, L Anez-Bustillos, M Deiana, ...Antioxidants 10 (5), 799, 2021202
3
2021
Trial in progress: the randomized, double-blind, placebo-controlled phase Ib CROSSWALK-a trial evaluating the safety of crovalimab for the management of acute uncomplicated …
P Bartolucci, KI Ataga, MU Callaghan, L De Franceschi, C Minniti, ...Blood 18, 108, 2021202
3
2021
Transfusional Approach in Multi-Ethnic Sickle Cell Patients: Real-World Practice Data From a Multicenter Survey in Italy
G Graziadei, L De Franceschi, L Sainati, D Venturelli, N Masera, ...Frontiers in Medicine 9, 82154, 2022202
3
2022
Acute haemolysis by cold antibody during SARS-CoV-2 infection in a patient with Evans syndrome: a case report and literature review
N Osti, J Ceolan, P Piccoli, F Mazzi, R Montemezzi, F Dima, S Friso, ...Blood Transfusion 20 (2), 168, 2022202
3
2022
Allogenic bone grafts and postoperative surgical site infection: are positive intraoperative swab cultures predictive for a higher infectious risk?
A Ruffilli, F Barile, M Fiore, M Manzetti, G Viroli, A Mazzotti, M Govoni, ...Cell and Tissue Banking, 1-11, 0
2
2022

Referred From: https://scholar.google.it/citations?user=-Gc6tOkAAAAJ&hl=it

Cited by
Citations 21028
h-index 59
i10-index 160
Recommended Journals
Open Access Journals